Regression of coronary atherosclerosis: Current evidence and future perspectives

Trends in Cardiovascular Medicine

Volumn 26, Issue 2, 2016, Pages 150-161

  Koskinas, Konstantinos C ^a   Windecker, Stephan ^a   Räber, Lorenz ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Atherosclerosis; Regression; Statin; Vulnerable plaque

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ATHEROGENESIS; ATHEROMA; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL REACTIVITY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; IN VIVO STUDY; INTRAVASCULAR ULTRASOUND; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REMISSION; REVIEW; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE; CLASSIFICATION; CORONARY ARTERY DISEASE; DISEASE COURSE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PLAQUE, ATHEROSCLEROTIC;

ANTICHOLESTEREMIC AGENTS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; HUMANS; PATIENT OUTCOME ASSESSMENT; PLAQUE, ATHEROSCLEROTIC;

EID: 84959102938     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2015.05.004     Document Type: Review

References (77)

1. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013, 368:2004-2013.
2. Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
3. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc 2004, 291:1071-1080.
4. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. J Am Med Assoc 2006, 295:1556-1565.
5. Nicholls S.J., Ballantyne C.M., Barter P.J., Chapman M.J., Erbel R.M., Libby P., et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011, 365:2078-2087.
6. Nissen S.E., Tuzcu E.M., Libby P., Thompson P.D., Ghali M., Garza D., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. J Am Med Assoc 2004, 292:2217-2225.
7. Tardif J.C., Gregoire J., L'Allier P.L., Anderson T.J., Bertrand O., Reeves F., et al. Effects of the acyl coenzyme A: cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004, 110:3372-3377.
8. Räber L., Taniwaki M., Zaugg S., Kelbæk H., Roffi M., Holmvang L., et al. Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. Eur Heart J 2015, 36:490-500.
9. Glagov S., Weisenberg E., Zarins C.K., Stankunavicius R., Kolettis G.J. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987, 316:1371-1375.
10. Mintz G.S., Garcia-Garcia H.M., Nicholls S.J., Weissman N.J., Bruining N., Crowe T., et al. Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies. EuroIntervention 2011, 6:1123-1130.
11. Jensen L.O., Thayssen P., Pedersen K.E., Stender S., Haghfelt T. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation 2004, 110:265-270.
12. Nissen S.E., Nicholls S.J., Wolski K., Nesto R., Kupfer S., Perez A., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. J Am Med Assoc 2008, 299:1561-1573.
13. Nissen S.E., Tuzcu E.M., Brewer H.B., Sipahi I., Nicholls S.J., Ganz P., et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006, 354:1253-1263.
14. Narula J., Nakano M., Virmani R., Kolodgie F.D., Petersen R., Newcomb R., et al. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol 2013, 61:1041-1051.
15. Stone G.W., Maehara A., Lansky A.J., de Bruyne B., Cristea E., Mintz G.S., et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011, 364:226-235.
16. Nair A., Margolis M.P., Kuban B.D., Vince D.G. Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation. EuroIntervention 2007, 3:113-120.
17. Nasu K., Tsuchikane E., Katoh O., Vince D.G., Virmani R., Surmely J.F., et al. Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopathology. J Am Coll Cardiol 2006, 47:2405-2412.
18. Funada R., Oikawa Y., Yajima J., Kirigaya H., Nagashima K., Ogasawara K., et al. The potential of RF backscattered IVUS data and multidetector-row computed tomography images for tissue characterization of human coronary atherosclerotic plaques. Int J Cardiovasc Imaging 2009, 25:471-478.
19. Thim T., Hagensen M.K., Wallace-Bradley D., Granada J.F., Kaluza G.L., Drouet L., et al. Unreliable assessment of necrotic core by virtual histology intravascular ultrasound in porcine coronary artery disease. Circ Cardiovasc Imaging 2010, 3:384-391.
20. Granada J.F., Kaluza G.L., Wilensky R.L., Biedermann B.C., Schwartz R.S., Falk E. Porcine models of coronary atherosclerosis and vulnerable plaque for imaging and interventional research. EuroIntervention 2009, 5:140-148.
21. Obaid D.R., Calvert P.A., McNab D., West N.E., Bennett M.R. Identification of coronary plaque sub-types using virtual histology intravascular ultrasound is affected by inter-observer variability and differences in plaque definitions. Circ Cardiovasc Imaging 2012, 5:86-93.
22. Yabushita H., Bouma B.E., Houser S.L., Aretz H.T., Jang I.K., Schlendorf K.H., et al. Characterization of human atherosclerosis by optical coherence tomography. Circulation 2002, 106:1640-1645.
23. Tearney G.J., Regar E., Akasaka T., Adriaenssens T., Barlis P., Bezerra H.G., et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol 2012, 59:1058-1072.
24. Moreno P.R., Lodder R.A., Purushothaman K.R., Charash W.E., O'Connor W.N., Muller J.E. Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by nearinfrared spectroscopy. Circulation 2002, 105:923-927.
25. Pu J., Mintz G.S., Brilakis E.S., et al. In vivo characterization of coronary plaques: novel findings from comparing greyscale and virtual histology intravascular ultrasound and near-infrared spectroscopy. Eur Heart J 2012, 33:372-383.
26. von Birgelen C., Hartmann M., Mintz G.S., Baumgart D., Schmermund A., Erbel R. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (≥12 months) follow-up intravascular ultrasound. Circulation 2003, 108:2757-2762.
27. Puri R., Nissen S.E., Ballantyne C.M., Barter P.J., Chapman M.J., Erbel R., et al. Factors underlying regression of coronary atheroma with potent statin therapy. Eur Heart J 2013, 34:1818-1825.
28. Bayturan O., Kapadia S., Nicholls S.J., Tuzcu E.M., Shao M., Uno K., et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol 2010, 55:2736-2742.
29. Puri R., Nissen S.E., Libby P., Shao M., Ballantyne C.M., Barter P.J., et al. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation 2013, 128:2395-2403.
30. Stegman B., Puri R., Cho L., Shao M., Ballantyne C.M., Barter P.J., et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care 2014, 37:3114-3120.
31. Nicholls S.J., Tuzcu E.M., Kalidindi S., Wolski K., Moon K.W., Sipahi I., et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 2008, 52:255-262.
32. Nicholls S.J., Wolski K., Sipahi I., Schoenhagen P., Crowe T., Kapadia S.R., et al. Rate of progression of coronary atherosclerotic plaque in women. J Am Coll Cardiol 2007, 49:1546-1551.
33. Puri R., Nissen S.E., Shao M., Ballantyne C.M., Barter P.J., Chapman M.J., et al. Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. JACC Cardiovasc Imaging 2014, 7:1013-1022.
34. Gutierrez J., Ramirez G., Rundek T., Sacco R.L. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med 2012, 172:909-919.
35. Koskinas K.C., Feldman C.L., Chatzizisis Y.S., Coskun A.U., Jonas M., Maynard C., et al. Natural history of experimental coronary atherosclerosis and vascular remodeling in relation to endothelial shear stress: a serial, in vivo intravascular ultrasound study. Circulation 2010, 121:2092-2101.
36. Nicholls S.J., Tuzcu E.M., Crowe T., Sipahi I., Schoenhagen P., Kapadia S., et al. Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol 2006, 47:1967-1975.
37. Calvert P.A., Obaid D.R., O'Sullivan M., Shapiro L.M., McNab D., Densem C.G., et al. Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study. JACC Cardiovasc Imaging 2011, 4:894-901.
38. Lin F.Y., Shaw L.J., Dunning A.M., Labounty T.M., Choi J.H., Weinsaft J.W., et al. Mortality risk in symptomatic patients with nonobstructive coronary artery disease: a prospective 2-center study of 2,583 patients undergoing 64-detector row coronary computed tomographic angiography. J Am Coll Cardiol 2011, 58:510-519.
39. Stone P.H., Saito S., Takahashi S., Makita Y., Nakamura S., Kawasaki T., et al. Prediction of progression of coronary artery disease and clinical outcomes using vascular profiling of endothelial shear stress and arterial plaque characteristics: the PREDICTION Study. Circulation 2012, 126:172-181.
40. Puri R., Nissen S.E., Shao M., Ballantyne C.M., Barter P.J., Chapman M.J., et al. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. Eur Heart J 2013, 34:3182-3190.
41. von Birgelen C., Hartmann M., Mintz G.S., van Houwelingen K.G., Deppermann N., Schmermund A., et al. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 2004, 110:1579-1585.
42. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
43. Nicholls S.J., Hsu A., Wolski K., Hu B., Bayturan O., Lavoie A., et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol 2010, 55:2399-2407.
44. Kawasaki M., Sano K., Okubo M., Yokoyama H., Ito Y., Murata I., et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol 2005, 45:1946-1953.
45. Hattori K., Ozaki Y., Ismail T.F., Okumura M., Naruse H., Kan S., et al. Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter IVUS. JACC Cardiovasc Imaging 2012, 5:169-177.
46. Serruys P.W., García-García H.M., Buszman P., Erne P., Verheye S., Aschermann M., et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008, 118:1172-1182.
47. Puri R., Libby P., Nissen S.E., Wolski K., Ballantyne C.M., Barter P.J., et al. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging 2014, 15:380-388.
48. Puato M., Faggin E., Rattazzi M., Zambon A., Cipollone F., Grego F., et al. Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a non-statin-based regimen in patients undergoing carotid endarterectomy. Stroke 2010, 41:1163-1168.
49. Kini A.S., Baber U., Kovacic J.C., Limaye A., Ali Z.A., Sweeny J., et al. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol 2013, 62:21-29.
50. Oemrawsingh R.M., Cheng J.M., García-García H.M., van Geuns R.J., de Boer S.P., Simsek C., et al. Near-infrared spectroscopy predicts cardiovascular outcome in patients with coronary artery disease. J Am Coll Cardiol 2014, 64:2510-2518.
51. Takarada S., Imanishi T., Kubo T., Tanimoto T., Kitabata H., Nakamura N., et al. Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study. Atherosclerosis 2009, 202:491-497.
52. Komukai K., Kubo T., Kitabata H., Matsuo Y., Ozaki Y., Takarada S., et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol 2014, 64:2207-2217.
53. Tawakol A., Fayad Z.A., Mogg R., Alon A., Klimas M.T., Dansky H., et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol 2013, 62:909-917.
54. Fifer K.M., Qadir S., Subramanian S., Vijayakumar J., Figueroa A.L., Truong Q.A., et al. Positron emission tomography measurement of periodontal 18F-fluorodeoxyglucose uptake is associated with histologically determined carotid plaque inflammation. J Am Coll Cardiol 2011, 57:971-976.
55. Virmani R., Kolodgie F.D., Burke A.P., Finn A.V., Gold H.K., Tulenko T.N., et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005, 25:2054-2061.
56. Kolodgie F.D., Gold H.K., Burke A.P., Fowler D.R., Kruth H.S., Weber D.K., et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003, 349:2316-2325.
57. Giannoglou G.D., Koskinas K.C., Tziakas D.N., Ziakas A.G., Antoniadis A.P., Tentes I.K., et al. Total cholesterol content of erythrocyte membranes and coronary atherosclerosis: an intravascular ultrasound pilot study. Angiology 2009, 60:676-682.
58. Koskinas K.C., Giannoglou G.D. Intraplaque hemorrhage, RBC-derived cholesterol, and plaque progression: time to move from conjecture to evidence?. JACC Cardiovasc Imaging 2012, 5:1185-1186.
59. Sluimer J.C., Kolodgie F.D., Bijnens A.P., et al. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J Am Coll Cardiol 2009, 53:1517-1527.
60. Sun J., Underhill H.R., Hippe D.S., Xue Y., Yuan C., Hatsukami T.S. Sustained acceleration in carotid atherosclerotic plaque progression with intraplaque hemorrhage: a long-term time course study. JACC Cardiovasc Imaging 2012, 5:798-804.
61. Jain R.K., Finn A.V., Kolodgie F.D., Gold H.K., Virmani R. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nat Clin Pract Cardiovasc Med 2007, 4:491-502.
62. Libby P. How does lipid lowering prevent coronary events? New insights from human imaging trials. Eur Heart J 2015, 36:472-474.
63. Stein E.A., Mellis S., Yancopoulos G.D., Stahl N., Logan D., Smith W.B., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012, 366:1108-1118.
64. Raal F.J., Stein E.A., Dufour R., Turner T., Civeira F., Burgess L., et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015, 385:331-340.
65. Everett B.M., Pradhan A.D., Solomon D.H., Paynter N., Macfadyen J., Zaharris E., et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013, 166:199-207.
66. Ridker P.M., Howard C.P., Walter V., Everett B., Libby P., Hensen J., et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012, 126:2739-2748.
67. Freigang S., Ampenberger F., Weiss A., Kanneganti T.D., Iwakura Y., Hersberger M., et al. Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1α and sterile vascular inflammation in atherosclerosis. Nat Immunol 2013, 14:1045-1053.
68. Rheea J.W., Wua J.C. Advances in nanotechnology for the management of coronary artery disease. Trends Cardiovasc Med 2013, 23:39-45.
69. Broz P., Ben-Haim N., Grzelakowski M., Marsch S., Meier W., Hunziker P. Inhibition of macrophage phagocytotic activity by a receptor-targeted polymervesicle-based drug delivery formulation of pravastatin. J Cardiovasc Pharmacol 2008, 51:246-252.
70. Cho B.H., Park J.R., Nakamura M.T., Odintsov B.M., Wallig M.A., Chung B.H. Synthetic dimyristoylphosphatidylcholine liposomes assimilating into high-density lipoprotein promote regression of atherosclerotic lesions in cholesterol-fed rabbits. Exp Biol Med 2010, 235:1194-1203.
71. Douglas P.S., Hoffmann U., Patel M.R., Mark D.B., Al-Khalidi H.R., Cavanaugh B., et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med 2015, 372:1291-1300.
72. Miller J.M., Rochitte C.E., Dewey M., Arbab-Zadeh A., Niinuma H., Gottlieb I., et al. Diagnostic performance of coronary angiography by 64-row CT. N Eng J Med 2008, 359:2324-2336.
73. Wykrzykowska J.J., Diletti R., Gutierrez-Chico J.L., van Geuns R.J., van der Giessen W.J., Ramcharitar S., et al. Plaque sealing and passivation with a mechanical self-expanding low outward force nitinol vShield device for the treatment of IVUS and OCT-derived thin cap fibroatheromas (TCFAs) in native coronary arteries: report of the pilot study vShield Evaluated at Cardiac hospital in Rotterdam for Investigation and Treatment of TCFA (SECRITT). EuroIntervention 2012, 8:945-954.
74. Wiebe J., Nef H.M., Hamm C.W. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol 2014, 64:2541-2551.
75. Puricel S., Arroyo D., Corpataux N., Baeriswyl G., Lehmann S., Kallinikou Z., et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol 2015, 65:791-801.
76. Brugaletta S., Gori T., Low A.F., Tousek P., Pinar E., Gomez-Lara J., et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study. JACC Cardiovasc Interv 2015, 8:189-197.
77. Virmani R., Kolodgie F.D., Burke A.P., Farb A., Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000, 20:1262-1275.